PMN — ProMIS Neurosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $20.92m
- $7.60m
- 14
- 61
- 18
- 21
Annual cashflow statement for ProMIS Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -4.22 | -9.79 | -18.1 | -13.2 | 2.78 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.309 | 2 | -4.39 | -0.597 | -18.2 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.654 | -1.56 | 5.4 | 2.94 | -11.7 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -3.25 | -9.31 | -17 | -10.8 | -27.2 |
| Capital Expenditures | -0.081 | -0.006 | -0.002 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.002 | 0.101 | 0 | -0.001 | -0.001 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.083 | 0.095 | -0.002 | -0.001 | -0.001 |
| Financing Cash Flow Items | 0 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.86 | 25.5 | 6.49 | 17.7 | 27.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.472 | 16.1 | -11.1 | 6.72 | 0.693 |